Table 1.
Characteristics of allo-HSCT patients with PGF and GGF
| Characteristics | PGF* (n = 20) | GGF* (n = 40) | P value** |
|---|---|---|---|
| BM evaluated time (post-HSCT days) | 102 (53–152) | 92.5 (24–561) | 0.14 |
| Blood cell count | |||
| Median WBC (×109/L) (range) | 1.1 (0.3–2.7) | 5.01 (1.93–9.83) | <0.0001 |
| Median ANC (×109/L) (range) | 0.7 (0.1–1.8) | 2.62 (0.84–7.1) | 0.0007 |
| Median Hb (g/L) (range) | 83 (68–104) | 114.5 (85–165) | <0.0001 |
| Median PLT (×109/L) (range) | 29 (4–53) | 149.5 (31–266) | <0.0001 |
| Age at HSCT (years, median, range) | 33.5 (11–62) | 26 (7–51) | 0.10 |
| Gender (male/female) | 15/5 | 24/16 | 0.39 |
| Underlying disease | 0.78 | ||
| AML | 6 | 14 | |
| ALL | 9 | 16 | |
| CML | 0 | 2 | |
| MDS | 3 | 4 | |
| sAA | 2 | 4 | |
| Status at HSCT | 0.54 | ||
| Standard-risk | 4 | 12 | |
| High-risk | 16 | 24 | |
| Source of stem cell | 0.99 | ||
| BM and G-PB | 19 | 38 | |
| G-PB | 1 | 2 | |
| Transplanted total nucleated cell dose (×108/kg, median, range) | 8.08 (6.01–14.49) | 7.615 (5.22–13.81) | 0.68 |
| Transplanted CD34+ cell dose (×108/kg, median, dose) | 2.29 (1.18–0.5.28) | 2.49 (0.85–6) | 0.09 |
| Donor match | 0.34 | ||
| HLA-identical unrelated donor | 1 | 2 | |
| HLA-identical sibling donor | 3 | 12 | |
| HLA-partially matched related | 16 | 26 | |
| Sex mismatch | 0.99 | ||
| Female to male | 5 | 9 | |
| Female to female | 2 | 2 | |
| Male to female | 4 | 13 | |
| Male to male | 9 | 16 | |
| ABO mismatch | 0.47 | ||
| No | 12 | 26 | |
| Minor | 3 | 6 | |
| Major | 5 | 8 | |
| Pre-HSCT cycles of chemotherapy | 4 (0–6) | 3.5 (0–11) | 0.86 |
| Conditioning | 0.34 | ||
| BU/CY | 3 | 12 | |
| BU/CY + ATG | 17 | 28 | |
| History of aGvHD | 13 | 21 | 0.77 |
| History of CMV reactivation | 17 | 24 | 0.08 |
allo-HSCT allogeneic haematopoietic stem cell transplantation, PGF poor graft function, GGF good graft function, AML acute myelogenous leukemia, ALL acute lymphocytic leukemia, CML chronic myelogenous leukemia, MDS myelodysplastic syndrome, sAA sever aplastic anemia, HLA human leukocyte antigen, BU busulfan, CY cyclophosphamide; ATG anti-human thymus globulin; aGvHD acute graft-versus-host disease, CMV cytomegalovirus
* Group matching criteria included age at HSCT (±1 years), pre-HSCT cycles of chemotherapy (±1 cycle), disease status at HSCT and BM microenvironment evaluated time after HSCT (±5 days). For each PGF case, two GGF control was randomly selected from the same cohort at which the PGF occurred (“risk-set sampling”)
** The continuous variables were compared using the Mann–Whitney U test, and the differences in frequency between the 2 groups were compared using the Chi square test. The criterion for statistical significance was P < 0.05